Table 1.
Characteristics of studies included in this meta-analysis.
| Study | Year | Study type | Stage | Age | Intervention types | Number of patients | PD-L1 CPS≥1% |
PD-L1 CPS<1% |
PD-L1 CPS unknown | Follow-up (m), median (range) |
|---|---|---|---|---|---|---|---|---|---|---|
| Chunyan Lan | 2024 | NRCT single-arm, phase II | metastatic, recurrent, or persistent cervical cancer | 51 (33–67) | Camrelizumab | 45 | 10 | 30 | 5 | 6 (0.97–37.4) |
| Yin Wang | 2023 | NRCT single-arm, phase II | recurrent or metastatic cervical cancer | 50 (34–68) | Sintilimab | 27 | 18 | 5 | 4 | 10.2 (3.0–24.5) |
| Lingfang Xia | 2022 | NRCT single-arm, phase II | recurrent or metastatic cervical cancer | 50 (43–55) | Camrelizumab | 33 | 10 | 9 | 14 | 13.6 (10.0–23.6) |
| Hyun Cheol Chung | 2019 | international, open-label, multicohort | advanced Cervical Cancer | 46 (24–75) | Pembrolizumab | 98 | 82 | 15 | 1 | 10.2 (0.6–22.7) |
| Kenji Tamura | 2019 | prospective, multicenter, open-label | advanced or recurrent uterine cervical cancer | 50 (32–68) | Nivolumab | 20 | 5 | 15 | / | 5.4 (1.0–13.9) |